How is heparin‑induced thrombocytopenia (HIT) diagnosed?

Diagnosis of Heparin-Induced Thrombocytopenia

Diagnose HIT using a two-step approach: first calculate the 4T score to determine clinical probability, then confirm with laboratory testing using immunoassays (for screening) followed by functional assays (for confirmation). 1

Step 1: Clinical Assessment with 4T Score

Use the 4T score to stratify pre-test probability in all patients with suspected HIT outside of cardiac surgery contexts 1. The 4T score evaluates four criteria (0-2 points each):

• Thrombocytopenia severity: Platelet count <100 G/L AND >50% decrease from baseline (most important criterion) 1
• Timing: Typically days 5-14 of heparin therapy; can occur earlier (<5 days) if recent heparin exposure within 3 months, or later (>3 weeks, especially with LMWH) 1
• Thrombosis or other sequelae: New thrombosis, skin necrosis, or acute systemic reactions after heparin bolus
• Other causes of thrombocytopenia: Assess alternative explanations

Key timing considerations:

• Standard onset: Days 5-14 of therapy
• Rapid onset: Day 1 if heparin exposure within past 3 months 1
• Delayed onset: Can occur up to several weeks after stopping heparin 2

Step 2: Laboratory Testing Algorithm

Initial Screening: Immunoassays

Order immunoassays first as they are widely available, highly sensitive (~95%), and provide rapid results 3:

• Enzyme-linked immunosorbent assay (ELISA) detecting anti-PF4/heparin antibodies
• Rapid automated assays: Chemiluminescence (CLIA) or latex immunoturbidimetric assay (LIA) for real-time results 4

Critical caveat: Immunoassays have high false-positive rates because they cannot distinguish pathogenic from non-pathogenic antibodies 3. Use IgG-specific assays and interpret quantitatively—strong positive results have better specificity 4.

Confirmatory Testing: Functional Assays

Functional assays are the diagnostic gold standard and must be performed to confirm HIT 3:

• Serotonin release assay (SRA): ~95% sensitivity and specificity 3, 4
• Heparin-induced platelet activation test (HIPA): Alternative functional assay 3

These assays detect platelet-activating antibodies and distinguish pathogenic from non-pathogenic antibodies. However, they are technically demanding, time-consuming, and not available in most hospitals 3.

Emerging Technology: Flow Cytometry

Flow cytometry detecting procoagulant platelet formation shows promise as an alternative functional assay that may be more accessible than SRA/HIPA 3. This measures phosphatidylserine externalization induced by HIT antibodies, but requires standardized protocols before widespread clinical implementation 3.

Clinical Triggers for Suspicion

Monitor platelet counts and suspect HIT in any heparinized patient with 1:

• Unexplained thrombocytopenia or >50% platelet drop
• New or worsening thrombosis (venous or arterial)
• Skin necrosis at injection sites
• Acute systemic reactions after heparin (chills, hypotension, dyspnea, amnesia)

Monitoring Strategy

For high-risk patients (cardiac surgery, orthopedic surgery, ICU): Check platelets 2-3 times weekly from day 4-14, then weekly up to 1 month 1

For low-risk patients: No routine monitoring needed, but check platelets with any unexpected clinical event 1

Always obtain baseline platelet count before starting heparin or within first 4 days 1

Important Pitfalls to Avoid

1. Don't rely on immunoassays alone—they have poor specificity and require functional assay confirmation 3
2. Don't dismiss early thrombocytopenia in patients with recent heparin exposure (within 3 months)—this can represent rapid-onset HIT 1
3. Don't forget delayed-onset HIT—can occur weeks after stopping heparin 2
4. Consider alternative diagnoses: Post-transfusion purpura, antiphospholipid syndrome, TTP, DIC, drug-induced thrombocytopenia, hemodilution, GPIIb-IIIa inhibitors 1
5. Recognize "autoimmune HIT" variants with heparin-independent antibodies detectable by SRA 4
6. Be aware of SRA-negative HIT—some patients have subthreshold platelet-activating antibodies requiring PF4-enhanced assays 4

Bayesian Interpretation

Use likelihood ratios from quantitative immunoassay results to adjust pre-test probability (from 4T score) into post-test probability 4:

• Strong positive: Dramatically increases HIT probability
• Weak positive: Modest increase
• Negative: Dramatically decreases HIT probability

The combination of intermediate-to-high 4T score plus positive functional assay confirms HIT diagnosis 3, 1, 4.